Sonnet biotherapeutics enters into clinical collaboration agreement to commence investigator-initiated and funded phase 1/2a study of son-1210 in combination with chemotherapy for the treatment of pancreatic cancer

Preclinical data has demonstrated the potential of son-1210, the first albumin-binding bifunctional il-12/il-15 fusion protein, for solid tumor immunotherapy

SONN Ratings Summary

SONN Quant Ranking